C
Ciclosporin
Availability of ACE Drug Guidance
Yes
Biologics Drug Information Overview
No
Post-marketing information
Dear Healthcare Professional Letters
Subsidy Information and Financing Scheme
Medical Assistance Fund
Standard Drug List
Active ingredient: Ciclosporin Synonym: Cyclosporine [USP]
General information
Subsidy Information and Financing Scheme
[SDL] Ciclosporin Capsule 10 mg, 25 mg, 100 mg
[SDL] Ciclosporin Infusion 50 mg/mL
[SDL] Ciclosporin Oral Solution 100 mg/mL
[MAF] Ciclosporin Eye Drops 0.1%
For the treatment of severe keratitis in dry eye disease in patients who fulfil the following criteria:
• Have a corneal fluorescein staining (CFS) grade of 4 using the modified Oxford scale or equivalent; AND
• Have an ocular surface disease index (OSDI) greater than or equal to 23; AND
• Inadequate symptom control using optimised treatment with tear substitutes for at least 3 months
Drug Guidance for Subsidy
19/12/2022 Ciclosporin 0.1% eye drops for treating severe vernal keratoconjunctivitis
[NR] The Ministry of Health’s Drug Advisory Committee has not recommended listing ciclosporin (CsA) 0.1% eye drops on the MOH List of Subsidised Drugs for treating severe vernal keratoconjunctivitis due to the uncertain clinical and cost effectiveness compared with current standard of care.
19/12/2022 Ciclosporin 0.1% eye drops for treating severe keratitis in dry eye disease
The Ministry of Health’s Drug Advisory Committee has recommended:
Ciclosporin 0.1% eye drops for treating severe keratitis in dry eye disease in patients who fulfil the following criteria:
Have a corneal fluorescein staining (CFS) grade of 4 using the modified Oxford scale or equivalent; AND
Have an ocular surface disease index (OSDI) greater than or equal to 23; AND
Inadequate symptom control using optimised treatment with tear substitutes for at least 3 months.
in view of acceptable proposal from the company.
Funding status
[R] Ciclosporin 0.1% eye drops, the only licensed ciclosporin eye preparation registered with the Health Sciences Authority, are recommended for inclusion on the Medication Assistance Fund (MAF) for the abovementioned indication from 1 February 2023.
[NR] MAF assistance does not apply to other strengths or extemporaneous preparations of ciclosporin eye drops.
Post Marketing Information
General Availability in Public Healthcare Institution
Note:
General availability information reflected is based on the Public Healthcare Institutions’ (PHI) formulary on what is commonly used for treating their patient population and may or may not be available for patients not under the care of that institution. It does not reflect the PHI’s actual inventory availability and is subjected to change. Please consult the Public Hospitals or Polyclinics for details on availability and supply restrictions/considerations. General availability is not tied to any brand unless otherwise stated.
Users are to consult the respective PHIs for actual inventory availability and supply restrictions/consideration
Availability information
Formulation | Public Healthcare Institution |
|---|---|
Capsule 10 mg |
|
Capsule 25 mg |
|
Capsule 100 mg |
|
Infusion 50 mg/mL |
|
Oral Solution 100 mg/mL |
|
Eye Drops 0.1% |
|
Registered Product(s) Information
Clinical and product info
Clinical info | Product Info |
|---|---|
Information under the Indication, Dosage and Contraindication sections are extracted from the relevant Package Insert/Patient Information Leaflet of the product available on HSA Infosearch. For more information, please refer to the product's Package Insert/ Patient Information Leaflet available on HSA Infosearch. The information provided is for informational purposes only, and is not exhaustive. The information provided is not a substitute for professional medical advice. Please consult a qualified healthcare provider for any medical advice. | Information available here are product details as registered with the HSA. As this website is updated monthly, please refer to HSA Infosearch for the most updated product information. |
Oral
* Clinical information is available for this product.
Ophthalmic
* Clinical information is available for this product.
Intravenous
* Clinical information is available for this product.